For instance, afatinib (BIBW 2992), an orally bioavailable small molecule inhibitor with activity against all members of the ErbB family, was subjected to evaluation in extensively pre-treated HER2-negative breast cancer patients through a phase II investigation. This evidence concerns the gene ERBB2 and breast cancer.